Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
Abstract Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well characterized. We describe the landscape of DLL3 at the mRNA and protein levels ac...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Portfolio
2024-11-01
|
| Col·lecció: | npj Precision Oncology |
| Accés en línia: | https://doi.org/10.1038/s41698-024-00739-y |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
